CHMP Recommends EU Approval of Roche PGx Drug Zelboraf | GenomeWeb

The European Commission's Committee for Medicinal Products for Human Use last eek recommended marketing authorization for Roche's Zelboraf as a monotherapy for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Zelboraf (vemurafenib) inhibits BRAF proteins that harbor a mutation at position 600, which causes cell proliferation in the absence of growth factors that would normally be required for proliferation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.